Search News Archives
Follow us on
Conferences | Events

Media Partners

 

Finnish Biomedical Start-Up Nightingale Health Obtains CE Mark for Blood Analysis Platform

publication date: Jul 27, 2017
 | 
author/source: Nightingale Health

Finnish biomedical startup Nightingale Health Ltd announced today CE marking for its blood biomarker analysis platform.

nightingale imageThe CE mark enables the clinical use of the analysis service and the analysed measures of creatinine and glucose in the EU region. 

Nightingale’s goal is to bring dozens of biomarkers included in the analysis platform gradually available for clinical use within the next year. The obtained CE mark is a remarkable step towards the company’s aim, enabling better prediction and targeted care for chronic diseases. 

Nightingale Health's blood biomarker analysis platform is based on NMR (Nuclear Magnetic Resonance) spectroscopy. It captures over 228 metabolic biomarkers from a single blood sample, transforming the possibility to understand molecular mechanisms and treatment effects of chronic diseases, such as cardiovascular disease, diabetes, and other metabolic diseases. To date, Nightingale Health’s blood biomarker analysis platform has been used by world leading medical universities and institutions and nearly half a million blood samples have been analysed with the technology. Nightingale Health’s quality management system has previously been certified according to EN ISO 13485 standard.

“The CE mark verifies the performance, reliability and repeatability of our blood analysis technology for clinical use according to our quality management system. We expect a rapid entry to the clinical market across Europe”, says Mr. Teemu Suna, Nightingale Health’s CEO and Co-founder. “We believe that our technology takes us one step closer to better prevention of chronic diseases. Therefore, we see this as a notable milestone, not only for our company but also for preventive medicine.”

Diabetes and cardiovascular diseases are one of the world’s biggest health problems. The global burden of diabetes has been evaluated at US $ 1.31 trillion, equivalent of 0,6 % of the world’s GDP.

Nightingale Health’s blood biomarker analysis platform

Nightingale Health’s biomarker analysis platform provides quantification of 228 metabolic measures from single sample with one test. The metabolites are quantified in absolute concentrations (e.g. mmol/l), so they can be applied both in healthcare and in medical research. The method is fully feasible for diagnostic use of individual biomarkers, research of multiple biomarker metabolic pathways, and the risk analytics of comprehensive metabolic diseases. The now obtained CE mark covers the clinical use of creatinine and glucose measures.


more about nightingale


 



 

Popular this month

 

In spite of Brexit, Cambridge and Oxford will need 40 football fields worth of lab space by 2023

Opportunities and challenges in the booming North American cannabis market

How To Increase Productivity & Efficiency In Laboratories

Wine Fraud: Chemical Fingerprint Uncorks Juicy Facts

Huge Savings Off Selected SiliCycle C8 and C18 SiliaChrom Plus HPLC Columns

New Edition of Focus Special Offers and New products Brochure Available from SLS

New Gilson Benchtop Instruments, The Perfect Complement to Your Workflow

Cell culture made easy with new 24-channel pipetting heads for VIAFLO 96/384

Tecan launches NGS DreamPrep™ for automated library preparation

Bruker Introduces new SKYSCAN 1273 Benchtop 3D X-ray Microscope

 


 

 

Can't find what you are looking for?


Search by company or by product


Company Name:

Product:





Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd